Industry Newsvoxzogoclinical trialsbiomarin
BioMarin Shows VOXZOGO Benefits When Started Early
|
4.9
BioMarin Pharmaceutical on March 12 released positive ongoing-trial data for VOXZOGO, its approved treatment for achondroplasia, reporting that initiating treatment before age two maximizes height gains and body proportions. The company said more than 5,000 children across 50+ countries have received VOXZOGO; infants under six months showed sustained improvements over four years, including 9.91 cm at 12 months and 15.62 cm at 24 months in Japan.
Scoring Rationale
Provides measurable early-treatment efficacy evidence, but limited credibility due to single-company reporting and promotional framing.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
